Wall Street Breakfast Eli Lilly shares hammered
7 snips
Aug 7, 2025 Eli Lilly's stock takes a hit despite encouraging data on its weight-loss drug. Labor productivity sees a rebound in Q2, creating some buzz in the markets. Meanwhile, Trump stirs the pot by calling for the firing of the Intel CEO. Warner Bros. Discovery shares mixed results, adding to the intrigue of the corporate landscape. Amazon makes strides in autonomous vehicles, highlighting innovation amidst economic shifts.
AI Snips
Chapters
Transcript
Episode notes
Weight-Loss Drugs Market Dynamics
- Eli Lilly's oral weight-loss drug showed significant weight loss but failed to excite investors due to valuation concerns.
- Novo Nordisk's similar drug fared better despite a lower growth outlook, highlighting market sensitivity to valuation and trial stage.
Warner Bros. Discovery Mixed Earnings
- Warner Bros. Discovery posted mixed earnings with weak streaming growth offsetting strong movie performance.
- The company's linear networks decline and stalled U.S. streaming growth highlight challenges for future revenue sustainability.
Fortinet Faces Upgrade Cycle Concern
- Fortinet faces concerns about slowing firewall upgrade cycles and flat product revenue excluding refresh benefits.
- Analysts worry the company is only halfway through a multi-year upgrade cycle critical to its growth.